BeyondSpring Inc. (BYSI) intrinsic value & 10-year financials

BeyondSpring Inc. (BYSI) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue reached to $0, with an average return on invested capital of 32.4%.

Graham intrinsic value
—
Share price (Oct 17, 2026)
$0.56
Revenue (FY2025)
$0
ROIC (10-yr avg)
32.4%
Free cash flow (FY2025)
-$19.8M

BYSI 10-year financial history

Fiscal year Revenue Net income EPS (diluted) Free cash flow Operating margin ROIC
FY2025 $0 -$1.0M — -$19.8M — 23.7%
FY2024 $0 -$11.1M — -$16.7M — 25.9%
FY2023 $0 -$21.0M — -$16.6M — 47.5%
FY2022 — — — — — —

Source: annual 10-K filings on SEC EDGAR. Figures in USD.

Executive summary

BeyondSpring Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.

BeyondSpring Inc. has earned high returns on invested capital, averaging 32.4% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.

BeyondSpring Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.

Benjamin Graham lens

BeyondSpring Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.

BYSI stock: frequently asked questions

Does BeyondSpring Inc. generate free cash flow?

BeyondSpring Inc. generated -$19.8M of free cash flow (operating cash flow minus capital expenditures) in fiscal 2025. Free cash flow was positive in 0 of the last 3 reported years.

What is BYSI's return on invested capital?

Average ROIC over the last 4 fiscal years was 32.4%, and average return on equity was 47.7%. Sustained ROIC above about 15% usually points to a durable competitive advantage.

Where does this BYSI data come from?

From BeyondSpring Inc.'s annual 10-K filings on SEC EDGAR, most recently filed May 13, 2026. Prices are end-of-day snapshots; valuations are formula outputs, not investment advice.

Similar pharmaceutical preparations stocks